Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CFTR | P13569 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30055825 | 0.86 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL27449738 | 0.83 | KDM4E (0.47) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL28067904 | 0.82 | CA12 (0.42) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL136404 | 0.82 | ALDH1A1 (0.55) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL8953058 | 0.81 | KDM4E (0.50) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL14059057 | 0.81 | CA12 (0.50) | GAAKDM4EMAPTHSD17B10ABL1 | |
| SCHEMBL2426826 | 0.80 | PTGER4 (0.54) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL27464602 | 0.80 | CA12 (0.43) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL19307715 | 0.79 | NPC1 (0.41) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL27092907 | 0.79 | ALDH1A1 (0.45) | ALDH1A1GAAKDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780084-B2 | Antibody-recruiting molecules for the treatment of cancer | YALE UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190192497-A1 | ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER | KLEO PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-5340808-A | Fused pyridazinoquinazolone derivatives as neurotrophic agents | WARNER LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1994011373-A1 | PYRIDAZINOQUINAZOLONE DERIVATIVES AS NEUROTROPHIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
| US-4251531-A | ANTIALLERGENS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1981-02-17 | — | — | US | disclosed |
| US-4159330-A | ANTIALLERGENS | CARLO ERBA S.P.A. (IT) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192497-A1 | ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER | PLAUR, C3AR1, C5AR1 | ALDH1A1 3673/4885GAA 2069/4885KDM4E 3571/4885 |
| US-10780084-B2 | Antibody-recruiting molecules for the treatment of cancer | PLAUR, C3AR1, C5AR1 | ALDH1A1 3673/4885GAA 2069/4885KDM4E 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.